Home / Going-concern warnings / Atara Biotherapeutics, Inc.
Filed 2026-03-16 路 Form 10-K 路 Accession 0001193125-26-108361 micro
Price before filing: $6.5 (2026-03-13 close, split/dividend-adjusted)
Market cap at flag: $82.7M (2026-03-16) 路 Latest: $138.0M (2026-10-16)
| Window | ATRA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -19.4% | +6.0% | -25.4% | 2026-04-15 |
| 90 days | +53.2% | +14.3% | +38.9% | 2026-06-15 |
| 180 days | +42.3% | +15.5% | +26.8% | 2026-09-14 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 3 insiders sold $515K (9 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-12 | Panacea Innovation Ltd (+1 joint filer) 10% owner | Sale | 80,554 | $6.07 | $489K | no | Form 4 |
| 2026-03-02 | Grant-Huerta Yanina Chief Accounting Officer | Sale | 24 | $5.08 | $122 | no | Form 4 |
| 2026-03-02 | Grant-Huerta Yanina Chief Accounting Officer | Sale | 1,603 | $5.08 | $8K | no | Form 4 |
| 2026-03-02 | Grant-Huerta Yanina Chief Accounting Officer | Sale | 377 | $5.08 | $2K | no | Form 4 |
| 2026-03-02 | Grant-Huerta Yanina Chief Accounting Officer | Sale | 100 | $5.08 | $508 | no | Form 4 |
| 2026-03-02 | Nguyen AnhCo President and CEO, Director | Sale | 198 | $5.08 | $1K | no | Form 4 |
| 2026-03-02 | Nguyen AnhCo President and CEO, Director | Sale | 58 | $5.08 | $295 | no | Form 4 |
| 2026-03-02 | Nguyen AnhCo President and CEO, Director | Sale | 1,298 | $5.09 | $7K | no | Form 4 |
| 2026-03-02 | Nguyen AnhCo President and CEO, Director | Sale | 1,442 | $5.09 | $7K | no | Form 4 |
| 2026-03-16: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-16 to 2026-04-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 2 to the financial statements, the Company's negative cash flow from operations and losses from operations raises substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Deloitte & Touche LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.